Arrieta, OscarBarrón-Barrón, FelicianoRamírez Tirado, Laura AlejandraZatarain-Barrón, Zyanya LuciaCardona-Mendoza, Andrés FelipeDíaz-García, DiegoYamamoto-Ramos, MasaoMota-Vega, BeatrizCarmona, AmirPeralta-Alvarez, Marco PoloBautista, YolandaAldaco, FernandoGerson, RaquelRolfo, ChristianRosell, Rafael Costa2020-05-122020-05-122374-2497https://hdl.handle.net/20.500.12495/2601application/pdfengEfficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG Phase 2 randomized clinical trialarticleNeoplasias pulmonaresInmunoterapiaDocetaxelTargeted and immune cancer therapyLung cancerOncologyhttps://jamanetwork.com/journals/jama/fullarticle/10.1001/jamaoncol.2020.0409?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jamaoncol.2020.0409instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquehttps://repositorio.unbosque.edu.coEfficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG Phase 2 randomized clinical trialAcceso cerradohttps://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessAcceso abierto2020